What changed
FDA announced 30 warning letters about compounded GLP-1 marketing, identifying sameness claims and branding that obscured the compounder.
What the evidence does not settle
FDA allegations, not court findings. The announcement does not establish later remediation or current operating status.
Evidence record
Event date: 2026-03-03. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.
Revision history
29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.